Plain-English translation of NCT05419726 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Obesity research guide →Researchers want to understand how semaglutide helps people lose weight. They believe it may work partly by activating brown adipose tissue — a special kind of fat in your body that burns calories to produce heat. This study will use imaging scans to measure whether the medication actually activates this calorie-burning fat in people.
While this medication has been shown to help people lose weight, doctors don't fully understand all the ways it works in the body. By studying this mechanism, researchers hope to find ways to make the treatment even more effective for weight loss and metabolic health.
You likely qualify if…
You likely don't qualify if…
You would undergo imaging scans (likely PET-CT scans) to measure the activity of your brown fat before and/or after starting semaglutide. The study involves about 20 participants total and is focused on research measurements rather than providing the medication itself — you would obtain and pay for semaglutide separately through your doctor.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
United States
Enrollment target
~20 participants
Started
February 2023
Primary completion
January 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Preethi Srikanthan, MD
Principal Investigator
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.